Preliminary data on mezigdomide plus dexamethasone and bortezomib in R/R multiple myeloma

(2:41)

The impact of renal impairment on clinical outcomes with mezigdomide plus dex in R/R myeloma

(1:49)

The safety \u0026 efficacy of mezigdomide plus dexamethasone and bortezomib or carfilzomib in R/R myeloma

(3:50)

Mezigdomide Plus Dexamethasone in RRMM: CC-92480-MM-002 Trial Results| Paul Richardson, MD |ASH 2023

(2:47)

Mezigdomide For Myeloma | Therapies on the Horizon

(3:54)

Mezigdomide plus dexamethasone and bortezomib or carfilzomib in R/R myeloma

(2:17)

Mezigdomide: New Drug Combination Trial Results for Multiple Myeloma Treatment

(10:24)

Mezigdomide + dexamethasone in novel combinations for R/R myeloma: insights into the CA057-003 trial

(2:52)

Mezigdomide (CC-92480) | Paul Richardson, MD | ASH 2022

(8:6)

Using the Immune System to Fight Multiple Myeloma

(13:19)

Venetoclax For Myeloma | Therapies on the Horizon #myeloma

(13:40)

What is HRMM (High-Risk Multiple Myeloma)? #myeloma

(5:59)

Shoulder Surgery - Post-op Diary - Day 2 | Tim Keeley | Physio REHAB

(4:21)

The Future of Myeloma Care | New York Roundtable October 19, 2024

(33:16)

Top Myeloma Research Presented at ASCO \u0026 EHA 2024

(1:2:1econd)

Living Well with Myeloma Webinar - New Drugs in Myeloma – What, How and When?

(1:1:52)

IMWG Conference Series 2024: Making Sense of Treatment

(59:50)

Jean-Sebastien Claveau, MD | Récents Développments de la Recherche en Myélome Multiple

(59:28)

IMF Patient \u0026 Family Webinar - New Frontiers In Myeloma Care

(3:3:13)

Benefits of CELMoDs over IMiDs in multiple myeloma

(2:31)

Results from CC-92480-MM-001: mezigdomide combined with dexamethasone in R/R multiple myeloma

(2:9)

CELMoDs® Mezigdomide | Paul Richardson, MD | IMS 2022

(1:51)

Mezigdomide: a novel CELMoD showing promise in the treatment of R/R myeloma

(2:21)

Recent updates on CELMoDs in multiple myeloma

(1:55)

SUCCESSOR-2 rationale: mezigdomide in combination with carfilzomib \u0026 dexamethasone for R/R myeloma

(1:41)

CC-92480 (mezigdomide) in R/R MM

(1:2)

Mezigdomide Combined with Dex in Relapsed/Refractory MM Pts: CC-92480-MM-001 Trial

(10:45)

ASH23: Mezigdomide (MEZI) Combo Therapy for Relapsed/Refractory Myeloma | Paul Richardson, MD

(11:42)

The evolving role of IMiDs

(5:36)